Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hunan 999 Nankai Pharmacy
Hunan, China999nk.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Two main products are approved and marketed in China:
- Binglian Qingyan Spray for pharyngitis (approved Oct 31, 2021)
- Zhining Tablets for hemorrhoids (approved Dec 27, 2019) No detailed clinical trial results publicly available.
- Therapeutic areas
- GastroenterologyInfectious Diseases
- Modalities
- Herbal medicine
- Industry
- Biotech
02
Partnerships
Parent company is part of the larger China Resources Pharmaceutical Group ecosystem.
Beyond the preview
Go deeper on Hunan 999 Nankai Pharmacy.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hunan 999 Nankai Pharmacy.